**1. Name and Address of Reporting Person**

Choi Jung

(Last) (First) (Middle)

C/O GLOBAL BLOOD THERAPEUTICS, INC.

181 OYSTER POINT BOULEVARD

SOUTH SAN FRANCISCO, CA 94080

**2. Issuer Name and Ticker or Trading Symbol**

Global Blood Therapeutics, Inc. [GBT]

**3. Date of Earliest Transaction (Month/Day/Year)**

08/01/2020

See Remarks

**4. If Amendment, Date of Original Filed (Month/Day/Year)**

08/01/2020

X Form filed by One Reporting Person

**5. Relationship of Reporting Person(s) to Issuer**

X Director

Owner (specify below)

10% Owner

**6. Individual or Joint/Group Filing (Check Applicable Line)**

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3 and 4)</th>
<th>5. Amount of Securities Beneficially Owned Following Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>07/31/2020</td>
<td>A</td>
<td>V</td>
<td>162(1)</td>
<td>A $36.68</td>
<td>161,670</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/01/2020</td>
<td>M</td>
<td>13,082</td>
<td>(2)</td>
<td>174,752</td>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/01/2020</td>
<td>F</td>
<td>6,239(3)</td>
<td>D</td>
<td>67.48</td>
<td>168,513</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>25,000</td>
<td>I By Trust</td>
<td></td>
</tr>
</tbody>
</table>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3 and 4)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
<th>Code V (A) (D)</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Units</td>
<td>(2)</td>
<td>08/01/2020</td>
<td>M</td>
<td>4,062</td>
<td>(4)</td>
<td>4,062 $0.00</td>
<td>Common Stock</td>
<td>4,062</td>
<td>$0.00</td>
<td>4,063 D</td>
<td>4,063 D</td>
<td>4,062</td>
<td>4,062</td>
<td>4,062</td>
<td>4,062</td>
<td></td>
</tr>
<tr>
<td>Restricted Stock Units</td>
<td>(2)</td>
<td>08/01/2020</td>
<td>M</td>
<td>2,875</td>
<td>(5)</td>
<td>2,875 $0.00</td>
<td>Common Stock</td>
<td>2,875</td>
<td>$0.00</td>
<td>8,625 D</td>
<td>8,625 D</td>
<td>2,875</td>
<td>2,875</td>
<td>2,875</td>
<td>2,875</td>
<td></td>
</tr>
<tr>
<td>Restricted Stock Units</td>
<td>(2)</td>
<td>08/01/2020</td>
<td>M</td>
<td>3,125</td>
<td>(6)</td>
<td>3,125 $0.00</td>
<td>Common Stock</td>
<td>3,125</td>
<td>$0.00</td>
<td>15,625 D</td>
<td>15,625 D</td>
<td>3,125</td>
<td>3,125</td>
<td>3,125</td>
<td>3,125</td>
<td></td>
</tr>
<tr>
<td>Restricted Stock Units</td>
<td>(2)</td>
<td>08/01/2020</td>
<td>M</td>
<td>3,020</td>
<td>(7)</td>
<td>3,020 $0.00</td>
<td>Common Stock</td>
<td>3,020</td>
<td>$0.00</td>
<td>21,140 D</td>
<td>21,140 D</td>
<td>3,020</td>
<td>3,020</td>
<td>3,020</td>
<td>3,020</td>
<td></td>
</tr>
</tbody>
</table>

**Explanation of Responses:**

1. Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(e).

2. Each Restricted Stock Unit (“RSU”) represents the right to receive one share of the Issuer's Common Stock.

3. Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 13,082 shares of Common Stock underlying the Reporting Person's RSUs.

4. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

5. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

6. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

7. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

**Remarks:**

Title: Chief Business and Strategy Officer

As/ Tricia Suvari, as Attorney-in-Fact 08/04/2020

**Signature of Reporting Person**

Date 08/04/2020

**Estimated average burden hours per response:** 0.5

**OMB Number:** 3235-0287

**Hours:** 0.5

**Footer:**

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

*If the form is filed by more than one reporting person, see Instruction 4(b)(v).*

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.